Dewpoint Therapeutics
Therapeutic drugs designed using biomolecular condensate biology to modulate intracellular protein organization
- Sector
- Biotech
- Headquarters
- Boston, MA
- Founded
- 2018
- Latest Form D
- $59.1M, Sep 2025
- Total capital
- $286M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $286M
- 3 Form D · last Sep 2025
- 13 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 35 pending · first 2022
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$59.1M
- Private capital raisedForm D · SEC · 2nd filing$150M
- Private capital raisedForm D · SEC · 1st filing$77.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ameet A. Nathwani, M.D.Director, Executive OfficerNamed in SEC Form D filings
- Amir H. NashatExecutive Officer, DirectorNamed in SEC Form D filings
- Amir H. Nashat, Ph.D.DirectorNamed in SEC Form D filings
- Anthony A. Hyman, Ph.D.DirectorNamed in SEC Form D filings
- Bruce H. BeutelExecutive OfficerNamed in SEC Form D filings
- Elisabeth A. LeidermanExecutive OfficerNamed in SEC Form D filings
Show all 22 people
- Fabio H. Pucci, Ph.D.DirectorNamed in SEC Form D filings
- Giuseeppe H. Ciaramella, Ph.D.DirectorNamed in SEC Form D filings
- Giuseppe H. Ciaramella, Ph.D.DirectorNamed in SEC Form D filings
- Guiseppe A. Ciaramella, Ph,D.DirectorNamed in SEC Form D filings
- Isaac A. Klein, M.D., Ph.D.Executive OfficerNamed in SEC Form D filings
- Joel D. SendekExecutive OfficerNamed in SEC Form D filings
- Juergen A. Eckhardt, M.D.DirectorNamed in SEC Form D filings
- Jurgen A. Eckhardt, M.D.DirectorNamed in SEC Form D filings
- Lori A. EscobedoExecutive OfficerNamed in SEC Form D filings
- Mark A. Murcko, Ph.D.DirectorNamed in SEC Form D filings
- Oliver H. Brandicourt, M.D.DirectorNamed in SEC Form D filings
- Olivier H. Brandicourt, M.D.DirectorNamed in SEC Form D filings
- Regina A. Barzilay, Ph.D.DirectorNamed in SEC Form D filings
- Richard A. Young, Ph.D.DirectorNamed in SEC Form D filings
- Srinivas H. Akkaraju, M.D.DirectorNamed in SEC Form D filings
- Srinivas Akkaraju, M.D., Ph.D.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 40- PendingModulators Of Beta Catenin And Uses ThereofUSPTOApplication 19563868
- PendingModulators Of Beta Catenin And Uses ThereofUSPTOApplication 19364191
- GrantedModulators Of Beta Catenin And Uses ThereofUSPTOUS 12,612,396
Show all 40 patent records
- Modulators Of Beta Catenin And Uses ThereofJul 16, 2026 · Application 19563868Pending
- Modulators Of Beta Catenin And Uses ThereofMay 7, 2026 · Application 19364191Pending
- Modulators Of Beta Catenin And Uses ThereofApr 28, 2026 · US 12,612,396Granted
- Methods Of Identifying Selective Condensate ModulatorsFeb 12, 2026 · Application 19100286Pending
- Methods Of Characterizing Condensate-associated Characteristics Of Compounds And Uses ThereofSep 25, 2025 · Application 18939875Pending
- Methods Of Screening For Condensate-associated Specificity And Uses ThereofSep 23, 2025 · US 12,422,437Granted
- Methods Of Characterizing Condensate-associated Characteristics Of Compounds And Uses ThereofDec 24, 2024 · US 12,174,198Granted
- Methods Of Isolating A Composition Comprising A Target MoleculeNov 14, 2024 · Application 18684592Pending
- Methods Of Identifying A Condensate Phenotype And Uses ThereofMay 2, 2024 · Application 18279760Pending
- Methods Of Identifying Interactions Of A Compound And A Condensate, Or A Component Thereof, And Uses ThereofOct 5, 2023 · Application 18020897Pending
- Compositions, Systems, And Methods For Identifying A Compound That Modulates One Or More Characteristics Associated With A RBM20 Condensate And/or A RBM20 PolypeptideNov 17, 2022 · Application 17761545Pending
- Methods Of Characterizing Condensate-associated Characteristics Of Compounds And Uses ThereofNov 8, 2022 · US 11,493,519Granted
- Methods Of Screening For Condensate-associated Specificity And Uses ThereofMay 24, 2022 · US 11,340,231Granted
- Amino Quinoline Compounds And Uses ThereofApplication 63618189Pending
- Identifying Compounds That Induce A Desired Phenotypic Response Of A Cell Using Machine LearningApplication 63531724Pending
- Methods Of Identifying Selective Condensate ModulatorsApplication PCTUS2023071541Pending
- B-catenin Depot Detection And Modulation AssaysApplication 63512560Pending
- Systems And Methods To Evaluate Condensate Knowledge GraphsApplication PCTUS2026012200Pending
- Amino Quinoline Compounds And Uses ThereofApplication PCTUS2025061608Pending
- Systems And Methods To Evaluate Condensate Knowledge GraphsApplication 63748738Pending
- Amino Quinoline Compounds And Uses ThereofApplication 63741592Pending
- Methods Of Isolating A Composition Comprising A Target MoleculeApplication PCTUS2022040890Pending
- Methods Of Identifying Selective Condensate ModulatorsApplication 63370354Pending
- New Condensate ParadigmsApplication PCTUS2022018282Pending
- Methods Of Identifying A Condensate Phenotype And Uses ThereofApplication PCTUS2022018311Pending
- Methods Of Identifying A Condensate Phenotype And Uses ThereofApplication 63298171Pending
- Methods Of Isolating A Composition Comprising A Target MoleculeApplication 63235594Pending
- Methods Of Identifying Interactions Of A Compound And A Condensate, Or A Component Thereof, And Uses ThereofApplication PCTUS2021045592Pending
- Methods Of Identifying A Condensate Phenotype And Uses ThereofApplication 63155683Pending
- Condensate ParadigmsApplication 63155685Pending
- Methods Of Screening For Condensate-associated Specificity And Uses ThereofApplication PCTUS2020051331Pending
- Compositions, Systems, And Methods For Identifying A Compound That Modulates One Or More Characteristics Associated With A RBM20 Condensate And/or A RBM20 PolypeptideApplication PCTUS2020051329Pending
- Compositions, Systems, And Methods For Identifying A Compound That Modulates One Or More Characteristics Associated With A RBM20 Condensate And/or A RBM20 PolypeptideApplication 63074985Pending
- Methods Of Identifying Interactions Of A Compound And A Condensate, Or A Component Thereof, And Uses ThereofApplication 63064867Pending
- Methods Of Characterizing Condensate-associated Characteristics Of Compounds And Uses ThereofApplication PCTUS2020017333Pending
- Methods Of Screening Compounds For Use In Treating DiseaseApplication 62902316Pending
- Methods For Identifying A Compound That Modulates A Characteristic Associated With A RBM20 Condensate And/or A RBM20 Polypeptide And Compositions ThereofApplication 62902309Pending
- Methods Of Characterizing Condensate-associated Characteristics Of CompoundsApplication 62866526Pending
- Methods Of Characterizing Condensate-associated Characteristics Of CompoundsApplication 62803365Pending
- Thienopyridine Compounds And Uses ThereofApplication 19603371Pending
Related companies, and why
- ProEncia Biotechnology Inc.Similar federal contract value in Biotech · null in contracts
- Metagenomi Technologies, LLCSimilar federal contract value in Biotech · null in contracts
- Harmony Biosciences II, Inc.Similar federal contract value in Biotech · null in contracts
- Neurona TherapeuticsSimilar federal contract value in Biotech · null in contracts
- CellanomeSimilar federal contract value in Biotech · null in contracts
- Rakuten Medical, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .